Kiernan Thomas J, Gersh Bernard J
Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Med Clin North Am. 2007 Jul;91(4):617-37; x. doi: 10.1016/j.mcna.2007.02.005.
ST-segment elevation myocardial infarction (STEMI) is still a major public health problem in the modern world. Therapeutic options have changed much over the last 20 years, with a shift in favor of mechanical reperfusion over pharmacologic reperfusion. Thrombolytic therapy still has much to offer in the management of STEMI, however, because many patients do not have timely access to a facility with the required expertise for establishing mechanical reperfusion. This review highlights the history of thrombolytic therapy, adjunctive therapies, the relationship with mechanical reperfusion, and potential roles for thrombolysis in the future.